Alpha Tau Medical Ltd

NASDAQ DRTS

Data sourced from

and

Daily

Download Data

Alpha Tau Medical Ltd Price to Earnings Ratio (P/E) on June 03, 2024: -21.12

Alpha Tau Medical Ltd Price to Earnings Ratio (P/E) is -21.12 on June 03, 2024, a -8.49% change year over year. The price to earnings ratio (P/E ratio) compares the market price per share of a company's stock to its earnings per share (EPS). It is calculated by dividing the market capitalization by the net income, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's earnings. A higher P/E ratio indicates that investors are willing to pay a higher price for each unit of earnings, suggesting higher market expectations for future earnings growth.

Alpha Tau Medical Ltd 52-week high Price to Earnings Ratio (P/E) is -8.81 on September 25, 2023, which is 58.27% above the current Price to Earnings Ratio (P/E).
Alpha Tau Medical Ltd 52-week low Price to Earnings Ratio (P/E) is -22.68 on May 17, 2024, which is -7.41% below the current Price to Earnings Ratio (P/E).
Alpha Tau Medical Ltd average Price to Earnings Ratio (P/E) for the last 52 weeks is -11.79.

NASDAQ: DRTS

Alpha Tau Medical Ltd

CEO	Mr. Uzi Sofer
IPO Date	March 8, 2021
Location	Israel
Headquarters	5 Kiryat Hamada Street, Jerusalem, Israel, 9777605
Employees	121
Sector	Healthcare
Industry	Biotechnology

Description

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Key trends